US Patent

US7947227 — Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO)

Method of Use · Assigned to Geno LLC · Expires 2026-10-17 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a nitric oxide delivery system that converts nitrogen dioxide to nitric oxide using a surface-active material and antioxidant.

USPTO Abstract

A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

Drugs covered by this patent

Inomax (NITRIC OXIDE) · Vero Biotech Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3037`	—	Inomax

Patent Metadata

Patent number: US7947227
Jurisdiction: US
Classification: Method of Use
Expires: 2026-10-17
Drug substance claim: No
Drug product claim: No
Assignee: Geno LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.